Special Encore: U.S. Pharmaceuticals - The Fu...

Our Strategist Michelle Weaver talks to Michael Zezas and Jessica Alsford, Co-Directors of the Morgan Stanley Institute, about how AI, energy resilience and industrial policy are changing investment decisions.Read more insights from Morgan Stanley.----- Transcript -----Michelle W ...  Show more

Our Global Head of Thematic and Sustainability Research Stephen Byrd explains why the recent AI infrastructure selloff may reflect technical pressures, not weakening fundamentals.Read more insights from Morgan Stanley.----- Transcript -----Stephen Byrd: Welcome to Thoughts on the ...  Show more

Mapping the human genome led to big advances in diagnosing rare disease. But diagnosis is only the first step in dealing with an illness. So what do you do if your child is found to have a condition that has no treatment? We hear from Michelle Teng, a mother who co-founded a biot ...  Show more

with Andrew Lo (@AndrewWLo) and Jorge Conde (@JorgeCondeBio)

The advent of new gene and cell therapies are beginning to approach that holy grail of medicine—that of a possible cure. But they are also more expensive than any medicines ever sold before. In this episode, M ...

The future is here. Gene silencing medicines - which can fine tune how our DNA works - have held promise for decades. Now hundreds of thousands of people will get them in the UK. James speaks to a surgeon whose life and career have been saved by gene-silencing drugs and to resear ...  Show more

Are rare diseases themselves rare? Neil deGrasse Tyson and comedian Chuck Nice learn about the science of gene therapy and how it can treat and potentially cure rare diseases with Gaurav Shah, CEO, Rocket Pharma.

NOTE: StarTalk+ Patrons can listen to this entire episode ...